EC grants label extension approval for Astellas' Xtandi for use in additional recurrent early prostate cancer treatment ...
Astellas Pharma Inc. announced the European Commission (EC) has approved a label extension for Xtandi (enzalutamide) as monotherapy or in combination with androgen deprivation therapy (ADT) for the treatment of adult men with high-risk biochemical …